The Pox-Protein Public Private Partnership (P5) – comprised of the Bill & Melinda Gates Foundation, the National Institutes of Health, Sanofi Pasteur, GlaxoSmithKline (GSK), the South African Medical Research Council, the HIV Vaccine Trials Network (HVTN), and the US Military HIV Research Program – is a diverse group of organizations committed to building upon the modest protective efficacy observed in the RV144 trial. If efficacious, a preventive vaccine could substantially impact the epidemic and improve public health by reducing the incidence of new infections globally.
Main Areas of Focus
- The modest protective efficacy observed in the RV144 trial led to the identification of the V2 antibody correlate hypothesis and the development of the P5
- The P5 program aims to improve upon the RV144 efficacy result and test the V2 hypothesis using vaccine constructs adapted for the subtype C epidemic in RSA